ArticleFrontiers in endocrinology2025
The association between a body shape index and diabetic kidney disease in early-onset type 2 diabetes: evidence from a two-center study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset type 2 diabetes mellitus (T2DM) is closely associated with an increased risk of diabetic kidney disease (DKD), and obesity is a well-recognized contributing factor. Traditional measures like body mass index (BMI) have limitations in capturing visceral fat distribution. The A Body Shape Index (ABSI), a newer anthropometric indicator, may provide a more accurate assessment of central obesity. This study investigated the relationship between ABSI and DKD in individuals with early-onset T2DM. Methods: This cross-sectional study analyzed data from 2,598 patients with early-onset T2DM enrolled at the National Metabolic Management Centers of Yuhuan Second People's Hospital and Taizhou Central Hospital between 2017 and 2024. Multivariate logistic regression models were used to evaluate the association between ABSI and DKD, with additional analyses using restricted cubic splines (RCS) to explore dose-response patterns. Subgroup and interaction analyses were also performed. Results: Of the participants, 1,030 (39.6%) were diagnosed with DKD. The prevalence of DKD increased across ABSI tertiles: 35.8% in the lowest tertile (T1), 38.5% in the middle tertile (T2), and 44.7% in the highest tertile (T3) (P < 0.001). Higher ABSI was independently associated with a greater risk of DKD (OR = 1.24; 95% CI: 1.05-1.50; P = 0.022) after adjusting for potential confounders. Patients in the highest ABSI tertile had a significantly higher risk of DKD than those in the lowest tertile (OR = 1.24; 95% CI: 1.01-1.52; P = 0.041). RCS analysis showed a positive linear relationship between ABSI and DKD risk (P for non-linearity = 0.139), and the findings were consistent across subgroups. Conclusion: ABSI is positively and linearly associated with the risk of DKD in patients with early-onset T2DM. This metric may be useful for identifying individuals at higher risk and guiding early preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.